TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Nefopam as a Multimodal Analgesia for Thoracic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient scheduled for elective video-assisted thoracoscopic surgery~* American Society of Anesthesiologists physical grade I, II, III~* patient aged from 18 years old~Exclusion Criteria:~* history of allergy in nonsteroidal anti-inflammatory drugs, or nefopam~* renal insufficiency~* liver insufficiency~* myocardial infarction~* glaucoma~* pregnant and lactating women at the time of surgery~* patient who did not consent to the use of patient-controlled analgesia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control group (Type: NO_INTERVENTION): Nefopam will not be administered in this group.
- nefopam group (Type: EXPERIMENTAL): Intravenous nefopam 20 mg will be administered twice, immediately after induction of anesthesia and at the end of surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~ages of 18 and 70 years had chronic cough of \>8 weeks in duration~Exclusion Criteria:~1. abnormal chest X ray, PNS view 2. previous surgical or endoscopic antireﬂux procedure 3. previous aerodigestive malignancy or Barrett's oesophagus 4. current smokers or ex-smok-ers (deﬁned as those who quit smoking \<3 months prior to study enrolment or those who have quit, but have a 20 pack year smoking history) 5. Malignancy History (lung cancer, esophageal cancer etc.) 6. upper respiratory infection within 8 weeks of study enrolment 7. currently using a PPI, H2 blocker, beta-blocker, angiotensin-converting enzyme inhibitor, corticosteroid, methylxanthine, inhaled beta-agonist, anti-inﬂammatory agent or anticholinesterase drug at time of enrolment

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- arm1-High dose PPI (Type: EXPERIMENTAL): None
- arm2-standard dose PPI (Type: ACTIVE_COMPARATOR): None
- arm3-placebo (Type: PLACEBO_COMPARATOR): Esomeprazole placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of INT-747 in Patients With Diabetes and Presumed NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes, defined by the American Diabetes Association (ADA), as one of the following criteria:~* Symptoms of diabetes plus casual plasma glucose concentration \>200 mg/dL (11.1 mmol/L) or~* Fasting plasma glucose \>126 mg/dL (7.0 mmol/L) or~* 2-hour post-load glucose \>200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance test (GTT).~* Presumed NAFLD, defined by one of the following criteria:~* Alanine aminotransferase (ALT) ≥47 U/L for females and ≥56 U/L for males~* Aspartate aminotransferase (AST) ≥47 U/L for females and ≥60 U/L for males~* Enlarged liver (demonstrated by ultrasound or other imaging technique)~* Diagnostic histological findings shown on prior biopsy (in the last 5 years).~Exclusion Criteria:~* Bilirubin \>2 × ULN~* ALT \>155 U/L for females and \>185 U/L for males.~* AST \>155 U/L for females and \>200 U/L for males.~* Patients taking any antidiabetic medications, with the exception of metformin and sulfonylureas. If the HbA1c is \<11%, patients may be enrolled who have been withdrawn from all other diabetic medications as specified in the protocol, at the discretion of the Principal Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 25 mg INT-747 (Type: ACTIVE_COMPARATOR): None
- 50 mg INT-747 (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with refractory angina as evidenced by at least one episode of ischemia (chest pain and/or ST-T changes) despite bed rest and at least 2 hours of treatment with oral or intravenous nitrates and intravenous heparin, or persistent newly developed negative T-waves occurring or continuing after at least 2 hours of treatment with oral or intravenous nitrates and intravenous heparin~* Having clinical signs and symptoms of angina at rest or minimal exertion with dynamic ST-segment and/or T-wave changes~* Having an episode of chest pain within 48 hours prior to the start of study agent administration~* Having a culprit lesion in a single native coronary vessel suitable for angioplasty on the qualifying angiogram~Exclusion Criteria:~* Patients who have had a recent myocardial infarction, unless CK has returned to less than twice the upper limit of normal~* Having features of ongoing ischemia that would require immediate intervention, or had a percutaneous transluminal coronary angioplasty (PTCA) within the past 24 hours~* Having an unprotected occlusion of the main left coronary artery \> 50%, a culprit lesion located in a venous or arterial bypass graft, or recent bleeding or a condition associated with increased bleeding risk~* Receiving concurrent administration of oral anticoagulants at the time of study entry, administration of intravenous dextran (prior to or planned for use during angioplasty), or planned administration of thrombolytic agent prior to or during angioplasty~* Having persistent hypertension at admission despite treatment, or a platelet count less than 100,000 per millimeter cubed

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Abciximab (c7E3 Fab) (Type: EXPERIMENTAL): Participants will receive 0.25 milligram per kilogram (mg/kg) of body weight abciximab as bolus intravenous injection followed by continuous infusion of abciximab at rate of 10 microgram per minute for at least 18 hours but not longer than 26 hours.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive matching placebo as bolus IV injection followed by continuous infusion of matching placebo for at least 18 hours but no longer than 26 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to DSM-5®. The current MDE must be confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient has a MADRS total score ≥24 at screening and baseline.~* The patient has had the current MDE for ≥3 months and \< 12 months.~* The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE with a partial response and is a candidate for a switch in the investigator's opinion.~* The patient wants to switch antidepressant treatment.~Exclusion Criteria:~* The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): 8 weeks treatment
- Desvenlafaxine (Type: ACTIVE_COMPARATOR): 8 weeks treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Physical Activity and Nutrition Intervention in Afterschool Programs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Programs that:~* Operate immediately after the school day~* Operate every day of the school year for a minimum of 2 hours~* Serve a minimum of 30 children of elementary age (6-12 years)~* Operate in a school, community or faith Setting~* Provide a snack~* Provide homework assistance/completion time~* Provide enrichment~* Provide opportunities for physical activity~* All children enrolled, staff, and afterschool program (ASP) leaders in the ASPs were eligible to participate in the study.~Exclusion Criteria:~* Programs that:~* Were singularly focused~* Programs that were physical activity focused~Children that:~* Have any physical and/or orthopedic impairment that would limit a child's ability to participate in regular physical activity.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Immediate Intervention (Type: EXPERIMENTAL): Over the 3 year project, this arm receives the Healthy Eating and Physical Activity intervention after year 1 (baseline) for a total of 2 years (year 2 and 3).
- Delayed Intervention (Type: EXPERIMENTAL): Over the 3 year project, this arm serves as the no treatment control/comparison group for year 1 and 2 (2 years of baseline) and receives the Healthy Eating and Physical Activity intervention in year 3 for a total of 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has at least 1 year history of migraine (with or without aura)~* Females of childbearing years must use acceptable contraception throughout trial~* Patient is in general good health based on screening assessment~Exclusion Criteria:~* Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)~* Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease~* Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)~* Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption~* Patient has a history of cancer within the last 5 years

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match assigned treatment arm; one orally-administered dose, plus an optional second dose of active drug, per assigned treatment arm, to treat a single moderate-to-severe migraine headache.
- MK0974 25 mg (Type: EXPERIMENTAL): MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 50 mg (Type: EXPERIMENTAL): MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 100 mg (Type: EXPERIMENTAL): MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 200 mg (Type: EXPERIMENTAL): MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 300 mg (Type: EXPERIMENTAL): MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 400 mg (Type: EXPERIMENTAL): MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- MK0974 600 mg (Type: EXPERIMENTAL): MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
- Rizatriptan 10 mg (Type: ACTIVE_COMPARATOR): Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Identification of Non-responders to Levothyroxine Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Poorly regulated hypothyroidism~* Female aged between 18 and 65 years~* Written informed consent obtained from the patient according to national regulations~Exclusion Criteria:~* Cardiovascular disease~* Chronic liver disease~* Chronic kidney disease~* Any other endocrinological disease~* Use of beta blockers~* Pregnant or lactating females~* Hormonal substitution other than T3 and T4~* Known psychiatric disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- T4 (Type: ACTIVE_COMPARATOR): None
- T3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects 12 years of age and older~* Clinical and/or electrographic seizures~Exclusion Criteria:~* Life expectancy of less than 24 hours~* Anoxic brain injury as primary cause of SE~* Recent (\<24 hour) traumatic brain injury as the primary cause of SE~* Administered anesthesia for the treatment of SE

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Ganaxolone active (Type: EXPERIMENTAL): Ganaxolone IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.
- IV Placebo, non-active (Type: PLACEBO_COMPARATOR): Placebo IV loading dose with continuous infusion (maintenance dose) for 2-4 days followed by an 18-hour taper.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Career Enhancement Training Study (USAF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Airmen-in-Training (AiT) in Technical Training classes in the 365 or 363 Training Squadrons of the 82 Training Wing (82 TRW)~* Eligible classes must be between 37-91 class days in length~Exclusion Criteria:~* Airmen from other countries receiving training in US~* Airmen who are not in their first year of enlistment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Wingman Connect (Type: EXPERIMENTAL): Wingman-Connect total training time is 5 hours, typically spread over three consecutive training 'blocks'(or days), plus 1-hour of booster training (one month later).
- Stress Management (Type: ACTIVE_COMPARATOR): The control training condition will consist of a 2 hr. informational training that provides an overview of the human stress response system and strategies to manage stress. The training will be delivered through lecture format using PowerPoint, supplemented by brief videos and interactive discussion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be male or female and at least 18 years of age.~* Female patients must be of:~* Non-childbearing potential;~* Childbearing potential, provided negative serum and urine pregnancy test and using effective contraception.~* 4 to 8 AK lesions on non-head locations.~Exclusion Criteria:~* Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected treatment area.~* Treatment with immunomodulators, or interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks.~* Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 8 weeks and 2 cm of treatment area

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): PEP005 (ingenol mebutate) Gel
- 2 (Type: PLACEBO_COMPARATOR): Vehicle gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Subclinical Cardiovascular Disease in Psoriatic Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a history of moderate to severe psoriatic disease~* Group 2: Healthy subjects without known psoriatic disease or cardiovascular disease~Exclusion Criteria:~* Unable to speak Spanish or English~* Active smoking (within the past year)~* Autoimmune, rheumatologic or inflammatory disease which are not psoriasis or psoriatic arthritis~* Known active cancer receiving treatment~* Pregnancy~* Anemia (hemoglobin \< 9 mg/dl) or thrombocytopenia (Platelet count \<75), or thrombocytosis (Platelet count \>600)~* A history of severe bleeding or bleeding disorders~* Current medication use which interact with either aspirin or atorvastatin~* Chronic kidney disease (CrCl \< 30ml/min)~* Congestive heart failure~* Currently taking aspirin or a statin.~* NSAID use within the past 48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Psoriatic Disease Patients (Type: OTHER): Moderate to severe psoriatic disease
- Healthy Control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Transfusion dependent thalassemia patients refractory to Hydroxyurea~Exclusion Criteria:~* Those with active systemic comorbidity, with past personal or family history of thrombophilia, recent fracture or recent major surgery

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thalidomide in combination with hydroxyurea (Type: EXPERIMENTAL): All the study patients refractory to hydroxyurea will be given thalidomide at an average dose of 2mg/kg/day (range 1-4mg/kg/day). Participants will also be continued on hydroxyurea at a dose of 10-20 mg/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete